ArticleJournal of translational medicine2025
Robo1 CAR-NK92 and radiotherapy exert synergistic efficacy in solid tumors.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer communications (London, England) · 2026Review
- A new era in CAR-NK cell therapy: from technological innovations to clinical applications.World journal of pediatrics : WJP · 2026Review
- PRMT3 in cancer: arginine methylation as a driver of tumor metabolism, immune evasion, and therapeutic resistance.Frontiers in immunology · 2026Review
- Advances in chimeric antigen receptor-natural killer cell therapy: from mechanisms and preclinical studies to clinical application.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in treating solid tumors is often limited, primarily due to the tumor microenvironment (TME), which hinders the recognition and infiltration of CAR-NK cells. Radiotherapy has been shown to modify the TME, enhance immune cell infiltration, and improve the recognition of tumor cells by immune cells. This study aimed to investigate the effects of combining radiotherapy with CAR-NK cells in a solid tumor model.
methodsThe Robo1 CAR-NK92 cell line was developed to specifically target Robo1. Tumor cell lines were generated following radiotherapy, and the cytotoxicity and infiltration of Robo1 CAR-NK92 cells in solid tumor models were evaluated both in vitro and in vivo post-radiotherapy.
resultsThe cytotoxicity of Robo1 CAR-NK92 cells against tumor cells was significantly enhanced following radiotherapy, likely due to the upregulation of NKG2D ligands on the surface of the tumor cells. Furthermore, tumor cells post-radiotherapy were found to promote the migration of Robo1 CAR-NK92 cells. In in vivo experiments, the combination of radiotherapy and Robo1 CAR-NK92 cells resulted in prolonged survival and improved tumor control in a solid tumor mouse model.
conclusionOur results indicate that the combination of Robo1 CAR-NK92 therapy and radiotherapy may present a promising approach for the treatment of solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.